Related Experiment Video
Updated: Mar 5, 2026
13:25
Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
6.7K
Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences
Mehdi Nematbakhsh1, Zahra Pezeshki, Fatemeh Eshraghi Jazi
1Water and Electrolytes Research Center, Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran. *Email: nematbakhsh@med.mui.ac.ir
Asian Pacific Journal of Cancer Prevention : APJCP
|March 28, 2017
Summary
Cisplatin chemotherapy causes kidney damage (nephrotoxicity), with no definitive supplement yet found to prevent it. Estrogen may offer kidney protection against this common chemotherapy side effect.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Cisplatin (CDDP) is a vital chemotherapeutic agent for solid tumors.
- Nephrotoxicity is a significant dose-limiting side effect of CDDP treatment.
- Current strategies to mitigate CDDP-induced nephrotoxicity lack definitive solutions.
Approach:
- This review synthesizes research on synthetic and herbal antioxidants as potential adjuncts to CDDP.
- Investigates the role of trace elements in preventing chemotherapy-induced kidney damage.
- Examines gender-related differences in CDDP nephrotoxicity, focusing on estrogen's protective potential.
Key Points:
- Numerous synthetic and herbal antioxidants have been explored, yielding mixed results.
- No single supplement has been conclusively identified to prevent CDDP nephrotoxicity.
- Estrogen's potential protective role against kidney damage from cisplatin warrants further investigation.
Conclusions:
- The search for effective adjuncts to prevent cisplatin nephrotoxicity remains ongoing.
- Understanding gender-specific mechanisms, like estrogen's influence, is crucial for future therapeutic development.
- Further research is needed to identify reliable supplements and therapeutic strategies to minimize chemotherapy-induced kidney damage.
More Related Videos
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
419
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
419
01:27Urinary Tract Calculi IV: Nutrition Therapy and Prevention
492
Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
492
01:11Renal Failure: Dose Adjustments
545
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
545
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
287
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
287
01:24Drug Toxicity: Risk factors
65
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
65
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
47
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
47